GSK to buy US cancer treatment firm Nuvalent for $10.6bn
Pusulam brief
British drugmaker GSK acquires US cancer specialist Nuvalent for $10.6bn to strengthen its oncology portfolio. The deal includes late-stage medications for lung cancer treatment.
Cancer research and treatment are among global health priorities. Major pharmaceutical investments in this field increase the likelihood of developing new therapeutic solutions.
British drugmaker’s new chief executive Luke Miels announces one of its biggest deals Business live – latest updates GSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based company that develops cancer drugs, including three for lung cancer. Continue reading...
Why good news?
Increased investment in cancer treatment development can accelerate drug innovation and expand patient treatment options. More therapeutic alternatives for serious diseases like lung cancer are becoming available.
Why it matters?
Cancer research and treatment are among global health priorities. Major pharmaceutical investments in this field increase the likelihood of developing new therapeutic solutions.
Reading rights
We do not have rights to republish the full article text from this source. Pusulam shows the open RSS context, source link, and its own analysis; use the source link for the full story.
Do you think this development will have a positive impact?
Pusulam AI
Chat with this story
Ask for a summary, why it matters, or missing context.
Source
For this source, we show summary, analysis, and open RSS context only. Read the full story at the source.
Read at source →